Sangamo Therapeutics, Inc., a genomic medicine company, will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy candidate for the treatment of hemophilia A that was being co-developed with, and licensed to Pfizer. Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo plans to explore all options to advance the program, including seeking a potential new collaboration partner.  Pfizer’...